Clinical Trials: Expedited Reporting Timelines

Global Reporting Timelines for Serious Adverse Events in Clinical Trials

Posted on digi By digi

In clinical research, reporting Serious Adverse Events (SAEs) within regulatory timelines is one of the most critical obligations under Good Clinical Practice (GCP). These timelines exist to ensure that regulators receive early warning of potential risks to participants and can take corrective actions if necessary. Failure to meet timelines often results in regulatory findings, ranging from FDA Form 483 observations to MHRA critical deficiencies, and in some cases trial suspension.
Click to read the full article.

Adverse Event Reporting and Management, Expedited Reporting Timelines

24-Hour Reporting Requirements for Serious Adverse Events in Clinical Trials

Posted on digi By digi

The 24-hour reporting requirement for Serious Adverse Events (SAEs) is a cornerstone of Good Clinical Practice (GCP). It ensures that potential safety risks are communicated immediately to sponsors, ethics committees, and regulatory authorities. Timely SAE reporting protects participants, enables rapid pharmacovigilance assessments, and ensures trial continuity.
Click to read the full article.

Adverse Event Reporting and Management, Expedited Reporting Timelines

When to Report SUSARs to Regulatory Authorities

Posted on digi By digi

A Suspected Unexpected Serious Adverse Reaction (SUSAR) is an event that meets three critical criteria: it is serious, it is related to the investigational product, and it is unexpected compared to the Investigator’s Brochure (IB) or product label. Only when all three conditions are satisfied does an SAE qualify as a SUSAR, triggering expedited regulatory reporting obligations.
Click to read the full article.

Adverse Event Reporting and Management, Expedited Reporting Timelines

Expedited Reporting Under EU-CTR and FDA Rules

Posted on digi By digi

Expedited reporting of Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) is a cornerstone of pharmacovigilance in clinical trials. Regulators worldwide mandate strict timelines so that new safety signals are identified and acted upon swiftly. Among the most influential frameworks are FDA 21 CFR 312.32 in the United States and EU-CTR 536/2014 in the European Union. Together, they set global benchmarks for expedited safety reporting obligations.
Click to read the full article.

Adverse Event Reporting and Management, Expedited Reporting Timelines

Timelines for Reporting Death and Life-Threatening Events in Clinical Trials

Posted on digi By digi

In clinical trials, death and life-threatening events represent the most serious categories of safety reporting. Regulators such as the FDA, EMA, MHRA, and CDSCO impose stricter timelines for reporting these events compared to other SAEs. The expedited rules ensure regulators receive immediate notification of critical risks that may threaten ongoing trial integrity or patient safety.
Click to read the full article.

Adverse Event Reporting and Management, Expedited Reporting Timelines

SOPs for Expedited Adverse Event Handling in Clinical Trials

Posted on digi By digi

Standard Operating Procedures (SOPs) form the backbone of pharmacovigilance systems in clinical research. Regulators including the FDA, EMA, MHRA, and CDSCO expect sponsors and CROs to maintain written SOPs that define workflows for adverse event (AE) and serious adverse event (SAE) reporting. When it comes to expedited reporting timelines (7 days, 15 days, and 24-hour notification windows), SOPs ensure compliance, consistency, and inspection readiness.
Click to read the full article.

Adverse Event Reporting and Management, Expedited Reporting Timelines

SOPs for Expedited Adverse Event Handling in Clinical Trials

Posted on digi By digi

Clinical trials involve inherent risks, and protecting participants requires rapid detection, classification, and reporting of safety events. Standard Operating Procedures (SOPs) serve as the foundation for ensuring that Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) are managed in compliance with global regulations. Regulators including the FDA (21 CFR 312.32), EMA (EU-CTR 536/2014), MHRA (UK), and CDSCO (India) mandate specific timelines for expedited reporting. SOPs ensure that these requirements are consistently met, preventing delays that could compromise participant safety or trigger inspection findings.
Click to read the full article.

Adverse Event Reporting and Management, Expedited Reporting Timelines

Role of the Sponsor in Timely SAE Reporting

Posted on digi By digi

In every clinical trial, the sponsor bears the ultimate responsibility for ensuring that Serious Adverse Events (SAEs) are reported accurately and within mandated timelines. While investigators detect and notify events, sponsors are accountable for causality assessment, classification, and expedited reporting to regulators. This distinction is enshrined in ICH E2A and GCP guidelines, which emphasize that sponsors cannot delegate accountability, even if day-to-day pharmacovigilance activities are outsourced to a CRO.
Click to read the full article.

Adverse Event Reporting and Management, Expedited Reporting Timelines

Safety Department Readiness for Expedited SAE Reports

Posted on digi By digi

The safety department, often referred to as the pharmacovigilance (PV) unit, plays a pivotal role in ensuring that Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) are reported within global expedited timelines. While investigators detect and report events, and sponsors hold ultimate responsibility, the safety department executes the operational tasks required to ensure compliance with regulatory expectations.
Click to read the full article.

Adverse Event Reporting and Management, Expedited Reporting Timelines

Reconciliation of SAE Timelines Across Regions

Posted on digi By digi

Clinical trials are increasingly multinational, spanning the United States, European Union, United Kingdom, India, and other regions. Each jurisdiction enforces specific rules for Serious Adverse Event (SAE) and Suspected Unexpected Serious Adverse Reaction (SUSAR) reporting. While timelines are harmonized in principle—7 days for fatal/life-threatening SUSARs and 15 days for others—implementation differs. For instance, FDA IND safety reports focus on IND-specific submissions, EMA requires central submissions through EudraVigilance, and CDSCO mandates investigators to notify regulators within 24 hours with causality reports in 10 days.
Click to read the full article.

Adverse Event Reporting and Management, Expedited Reporting Timelines